Skinvisible Web Sign Up for Updates         T 702.433.7154   |   F 702.433.7192
Skinvisible - Polymer Delivery System

The Ultimate Polymer Delivery System.

Skinvisible's Hand Sanitizer Kills "Super Bug" MRSA and E. coli For Up to 4 Hours

Studies Confirm One Application of DermSafe As An Effective Long-Lasting Hand Sanitizer

LAS VEGAS, Nevada. June 28, 2012 - Skinvisible Pharmaceuticals, Inc. (SKVI:OTCBB & OTCQB) today announced the successful completion of two new studies undertaken for DermSafe®, a non-alcohol hand sanitizer made with 4% Chlorhexidine Gluconate. The studies demonstrate the sustained (up to 4 hours) and potent killing of both gram-negative and gram-positive bacteria by DermSafe.

The studies proved the persistent ability of DermSafe on two different bacteria. This evaluation was based on ASTM 2752-10 Standard Guide for Evaluation of Residual Effectiveness of Antibacterial Personal Cleansing Products. The studies conducted by Bioscience Laboratories showed the difference between the number of challenge bacterial species recovered following exposure to the treated forearm skin of subjects and the number of bacteria recovered following exposure to untreated skin (control) from 1 hour and up to 4 hours following application of DermSafe.

The initial study tested DermSafe against Methicillin-resistant Staphylococcus aureus or MRSA (ATCC #33591), a "super bug" which is very prevalent in the community including hospital environments. The test results showed that DermSafe tested at 1 hour, 2 hours and 4 hours dramatically reduced MRSA with a kill of 93.39% at 4 hours. Even when the test sites were rinsed prior to each bacteria challenge, the test results showed a 95.83% reduction at the 4 hour time point.

The findings of the second study verified DermSafe's potent and increasing activity against Escherichia coli or E. coli (ATCC #43888") at both 2 and 4 hours with a 99.38% reduction at 4 hours.

"We are pleased with these new study results which solidify our previous studies conducted on DermSafe formulated with our patented Invisicare® technology. This new in-vivo data confirms the excellent persistency and efficacy profile of DermSafe", stated Mr. Terry Howlett, President and CEO. "We believe these new studies will benefit our licensees in both Canada and Europe in facilitating the marketing of DermSafe not only to the general public but for commercial use in hospitals, schools, law enforcement and the military ."

DermSafe is currently available from Alto Pharmaceuticals in Canada. Skinvisible is seeking additional licensees in select territories for commercial and/or retail markets.

  Press Release Index
New Press Release Alerts:


Click here to join our mailing list.
Home    |     About us    |    Technology    |    Products    |    Investors    |    Contact Us    |    Disclaimer & Privacy    |     Sign Up for Updates
© 2008 Skinvisible Pharmaceuticals, Inc.     Note: This website is not intended for Canadian residents.